APLN and diabetes mellitus: Recent clinical studies have identified apelin-13 as a potential biomarker in patients with CKD, suggesting a compensatory increase in response to renal impairment and cardiovascular disturbance regardless of the presence of diabetes (Sakran et al., 2025; Wang et al., 2024; Nyimanu et al., 2022).